Ultragenyx Pharmaceutical Inc. (RARE) Stock Price & How to Invest

Ultragenyx Pharmaceutical (NASDAQ: RARE) develops and sells treatments for rare and ultra-rare genetic diseases, conditions with small patient populations and often no approved therapy. Its commercial base includes Crysvita for X-linked hypophosphatemia (its largest product), Dojolvi for long-chain fatty acid oxidation disorders, Evkeeza, and Mepsevii, which together produced about $673 million of revenue in 2025. The company spans multiple modalities, protein-replacement, small molecule, antisense, and gene therapy, and is preparing several late-stage programs for potential approval.

The investment picture is that of a growing but still loss-making specialty biotech. Revenue grew roughly 20% in 2025, yet the company posted a net loss of about $575 million as it funds heavy R&D. Management has reaffirmed 2026 revenue guidance of $730 million to $760 million and reiterated a goal of reaching profitability in 2027, contingent on commercial growth, expense discipline, and monetizing potential priority review vouchers. The stock therefore trades largely on pipeline catalysts and the credibility of that profitability timeline rather than on current earnings.

Ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. The value concentrated in binary regulatory and clinical events (DTX401, UX111, and especially the GTX-102 Angelman readout) means a single negative outcome could sharply move the stock. Rare-disease revenue depends on small patient counts, payer reimbursement, and diagnosis rates, all of which can disappoint. The company faces well-capitalized competitors in gene therapy and orphan drugs, including BioMarin, Sarepta, and larger players. Finally, the 2027 profitability target is a management objective, not a guarantee, and could slip.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ultragenyx Pharmaceutical Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$670M
• FY2025 revenue: ~$673M (up ~20%)
• Q1 2026 revenue: ~$136M
• FY2025 net loss: ~$575M
• Cash and marketable securities: ~$737M (Dec 2025)
• Market cap: ~$2.6B

Ultragenyx trades at a modest multiple of revenue for a biopharma but has no earnings, so conventional P/E valuation does not apply. The market is effectively pricing the pipeline and the credibility of the 2027 profitability goal. Guidance for 2026 revenue is $730 million to $760 million, which excludes any potential new product launches.

There are three common ways to get RARE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so RARE sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where RARE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Ultragenyx is a real, revenue-generating rare-disease company whose valuation hinges on turning a deep pipeline into approvals and, eventually, profits.

Whether RARE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RARE a buy?, and where the stock could go from here in the RARE stock forecast.

For income investors, whether RARE pays a dividend and how the payout looks is covered in does RARE pay a dividend?